<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02962973</url>
  </required_header>
  <id_info>
    <org_study_id>CAR2016-01</org_study_id>
    <secondary_id>CIV-FR-16-09-016865</secondary_id>
    <nct_id>NCT02962973</nct_id>
  </id_info>
  <brief_title>European Clinical Evaluation of the Carmat Total Artificial Heart</brief_title>
  <acronym>ADVANCEHF</acronym>
  <official_title>Clinical Evaluation of the Carmat Total Artificial Heart for Patients With Advanced Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carmat SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Carmat SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this clinical investigation is to evaluate the safety and performance of the&#xD;
      Carmat Total Artificial Heart (TAH) in subjects with advanced heart failure requiring&#xD;
      biventricular support.&#xD;
&#xD;
      Each subject receiving the Carmat TAH will be evaluated at 6 months (180 days) for primary&#xD;
      and secondary endpoints with further follow-up assessments up to 2 years.&#xD;
&#xD;
      The results of the study will be used to support a CE mark application.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Center selection is based on the following: experience with VAD/TAH implantation and record&#xD;
      of good results in this patient population (% of survival), the infrastructure required to&#xD;
      perform the clinical investigation (especially the surgical and cardiology teams); site&#xD;
      resources and experience to manage the clinical study and the patient population; the&#xD;
      adherence to the standards of Good Clinical Practice. A specific focus during the site&#xD;
      selection is done on dedicated VAD - nurse team to ensure that:&#xD;
&#xD;
        -  Sites are experienced in the selection of patients whom require a mechanical circulatory&#xD;
           support. Social and psychological conditions of the patient and family must be&#xD;
           considered to ensure patient and family commitment in the care pathway,&#xD;
&#xD;
        -  Close supervision of patients on the use of the device (when changing batteries) by&#xD;
           experienced hospital professionals is guarantee;&#xD;
&#xD;
        -  Extensive hospital training program and regular support for patients and family -&#xD;
           relatives are ensured.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants with survival at 180 days</measure>
    <time_frame>180 days</time_frame>
    <description>Success is defined as survival at 180 days after Carmat TAH implantation or transplanted if before 180 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>180 days</time_frame>
    <description>Patient follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General health status change (1)</measure>
    <time_frame>180 days</time_frame>
    <description>Measured with the EuroQol EQ-5D questionnaire, a descriptive system of health-related quality of life states consisting of five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take one of five responses (EQ-5D-5L). The responses record five levels of severity (1:no problems; 2:slight problems; 3:moderate problems 4:severe problems; 5:extreme problems) within a particular EQ-5D dimension.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General health status change (2)</measure>
    <time_frame>180 days</time_frame>
    <description>Change as measured by the SF-36 questionnaire, consisting of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional status change</measure>
    <time_frame>180 days</time_frame>
    <description>New York Heart Association (NYHA) functional classification (regression scale I, II, III, IV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in functional status measured by the Six Minutes Walk Test</measure>
    <time_frame>180 days</time_frame>
    <description>The 6-min walk test is a submaximal exercise test that entails measurement of distance walked over a span of 6 minutes. The 6-minute walk distance provides a measure for integrated global response of multiple cardiopulmonary and musculoskeletal systems involved in exercise.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>180 days</time_frame>
    <description>Adverse Event Rates will be captured per the INTERMACS definitions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospital readmission rate</measure>
    <time_frame>180 days</time_frame>
    <description>Rate of unplanned readmissions to the hospital&#xD;
Frequency and incidence of all adverse events&#xD;
Frequency and incidence of pre-defined anticipated adverse events&#xD;
Frequency, incidence and type of device malfunction</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Advanced Heart Failure</condition>
  <arm_group>
    <arm_group_label>Carmat TAH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The surgical intervention takes place through a midsternotomy utilizing cardiopulmonary bypass. The device is then connected via a percutaneous driveline to an external controller and batteries and takes over the circulation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CARMAT TAH</intervention_name>
    <arm_group_label>Carmat TAH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgical intervention</intervention_name>
    <arm_group_label>Carmat TAH</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient age: 18 to 75 years&#xD;
&#xD;
          2. Inotrope dependent or cardiac Index (CI) &lt; 2.2 L/min/m2 if inotropes are&#xD;
             contra-indicated (heart failure due to restrictive or constrictive physiology).&#xD;
&#xD;
          3. On Optimal Medical Management as judged by the investigator based on current Heart&#xD;
             Failure practice guidelines (ESC/AHA)&#xD;
&#xD;
          4. Eligible to biventricular Mechanical Circulatory Support according to ISHLT guidelines&#xD;
             for mechanical circulatory support:&#xD;
&#xD;
               1. Biventricular failure with at least two of the following hemodynamic/&#xD;
                  echocardiographic measurements implying right heart failure:&#xD;
&#xD;
                    1. RVEF ≤ 30%&#xD;
&#xD;
                    2. RVSWI ≤ 0.25 mmHg*L/m2&#xD;
&#xD;
                    3. TAPSE ≤ 14mm&#xD;
&#xD;
                    4. RV-to-LV end-diastolic diameter ratio &gt; 0.72&#xD;
&#xD;
                    5. CVP &gt; 15 mmHg&#xD;
&#xD;
                    6. CVP-to-PCWP ratio &gt; 0.63&#xD;
&#xD;
                    7. Tricuspid insufficiency grade 4&#xD;
&#xD;
               2. Treatment-refractory recurrent and sustained ventricular tachycardia or&#xD;
                  ventricular fibrillation in the presence of untreatable arrhythmogenic pathologic&#xD;
                  substrate&#xD;
&#xD;
               3. Heart failure due to restrictive or constrictive physiology (e.g., hypertrophic&#xD;
                  cardiomyopathy, cardiac amyloidosis / senile or other infiltrative heart disease)&#xD;
&#xD;
          5. Anatomic compatibility confirmed using 3D imaging (CT-scan)&#xD;
&#xD;
          6. Patient's affiliation to health care insurance, if local requirement&#xD;
&#xD;
          7. Patient has signed the informed consent and committed to follow study requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Body Mass Index (BMI) &lt; 15 or &gt; 47&#xD;
&#xD;
          2. Existence of any ongoing non-temporary mechanical circulatory support&#xD;
&#xD;
          3. Existence of any temporary mechanical circulatory support other than IABP and Impella&#xD;
&#xD;
          4. History of cardiac or other organ transplant&#xD;
&#xD;
          5. Patients who have required cardiopulmonary resuscitation for &gt; 30 minutes within 14&#xD;
             days prior to implant&#xD;
&#xD;
          6. Known intolerance to anticoagulant or antiplatelet therapies&#xD;
&#xD;
          7. Coagulopathy defined by platelets &lt; 100k/μl or INR ≥ 1.5 not due to anticoagulant&#xD;
             therapy&#xD;
&#xD;
          8. Cerebro-vascular accident &lt; 3 months or symptomatic or a known &gt; 80% carotid stenosis&#xD;
&#xD;
          9. Known abdominal or thoracic aortic aneurysm &gt; 5 cm&#xD;
&#xD;
         10. End-organ dysfunction as per investigator judgment and following but not limited&#xD;
             criteria:&#xD;
&#xD;
               1. Total bilirubin &gt; 100 μmol/L (5,8 mg/dl) or cirrhosis evidenced by ultrasound,&#xD;
                  CT-scan or positive biopsy&#xD;
&#xD;
               2. GFR &lt; 30ml/min/1.73m2&#xD;
&#xD;
         11. History of severe Chronic Obstructive Pulmonary Disease or severe restrictive lung&#xD;
             disease&#xD;
&#xD;
         12. Recent blood stream infection (&lt;7 days)&#xD;
&#xD;
         13. Documented amyloid light-chain (AL amyloidosis)&#xD;
&#xD;
         14. Hemodynamically significant peripheral vascular disease accompanied by rest pain or&#xD;
             extremity ulceration&#xD;
&#xD;
         15. Illness, other than heart disease, that would limit survival to less than 1 year&#xD;
&#xD;
         16. Irreversible cognitive dysfunction, psychosocial issues or psychiatric disease, likely&#xD;
             to impair compliance with the study protocol and TAH management&#xD;
&#xD;
         17. Participation in any other clinical investigation that is likely to confound study&#xD;
             results or affect the study&#xD;
&#xD;
         18. Pregnancy or breast feeding (woman in age of childbearing will have to show negative&#xD;
             pregnancy test)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piet Jansen, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Carmat SA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elisabeth Vacher</last_name>
    <phone>+33 1 72 78 02 57</phone>
    <email>elisabeth.vacher@carmatsas.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute for Clinical and Experimental Medicine</name>
      <address>
        <city>Prague</city>
        <zip>140 21</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Righospitalet,</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Cardiaque - Institut Cœur Poumon</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andre Vincentelli, MD PhD</last_name>
      <phone>+33 3 20 44 59 62</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Pontchaillou Centre Cardio-Pneumologie</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erwan Flecher, MD</last_name>
      <phone>+33 (0)2 99 28 96 94</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>&quot;National Research Cardiac Surgery Center&quot;</name>
      <address>
        <city>Astana</city>
        <zip>010000</zip>
        <country>Kazakhstan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Kazakhstan</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 8, 2016</study_first_submitted>
  <study_first_submitted_qc>November 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2016</study_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced heart failure</keyword>
  <keyword>Total artificial heart</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

